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Positron emission tomography (PET) provides important
information in studies centered on the drug plasma concen-
trations–clinical effectiveness relationship, as it directly
allows measuring of drug binding to pharmacologically rele-
vant receptors in the brain. Such studies have been carried out
for many antipsychotics, the binding of which to central
dopamine D2 receptors can be observed with PET (Grunder
et al. 2011). A study showed a 50–70 % D2-receptor occu-
pancy by therapeutic doses (4–10 mg/day; 5.7±1.4 mg/day
[mean ± SD]) of the antipsychotic drug flupentixol, which
reportedly lead to flupentixol plasma concentrations between
0 and 6 ng/ml (1.47±0.97 ng/ml) after oral administration of
this drug to 13 patients (Reimold et al. 2007). Flupentixol is
available as a 1:1 mixture of the geometric isomers cis- and
trans-isomers (Z- and E-isomers, respectively) for oral admin-
istration, while the depot preparation flupentixol decanoate
contains only cis-flupentixol. Only cis-flupentixol is
considered to be pharmacologically active with regard to its
affinity for dopamine (and serotonin) receptors, as also shown
in clinical studies in which clinical efficacy of cis-flupentixol
(α-flupentixol; Z-flupentixol) was found to be superior to that
of trans-flupentixol (β-flupentixol; E-flupentixol) (Johnstone
et al. 1978). An analysis of three-dimensional structures and
molecular electrostatic potentials confirms the higher receptor
affinities of cis-flupentixol in comparison to the trans-isomer
(Sylte and Dahl 1991). In the already mentioned PET study
with flupentixol, the presented drug plasma concentrations
appear to be those of the sum of cis- and trans-flupentixol,
as the standard analytical technique used by MDS Pharma
Services (Fehraltorf, Switzerland) was not developed for the
separation of these isomers (Reimold et al. 2007; and Petra
Struwe, Celerion, Fehraltdorf, personal communication).
Recently, the AGNP-TDM group (Arbeitsgemeinschaft
für Neuropsychopharmakologie und Pharmakopsychiatrie)
(Hiemke et al. 2011) recommended published updated con-
sensus guidelines for therapeutic drug monitoring in psychi-
atry: The therapeutic reference range (recommended plasma
drug concentration) for the antipsychotic drug flupentixol
(flupenthixol) was given as 1–10 ng/ml. This range is relat-
ed to the sum of the cis- and the trans-isomers concentra-
tions, and the recommended range is mainly based on 2
studies (Reimold et al. 2007; Balant-Gorgia et al. 1985). The
question arises whether after analysis of the literature, which
considers pharmacological and pharmacokinetic differences
between the cis- and trans-isomers of flupentixol, the recom-
mended plasma concentration range of flupentixol may still be
considered as valid.
Only few studies considered the existence of two geo-
metric isomers of flupentixol differing by their properties. In
1985, a lower threshold of 2 ng/ml flupentixol was reported
for satisfactory antipsychotic effect (Balant-Gorgia et al.
1985). The authors did not use a stereoselective method,
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but divided the measured flupentixol concentration by 2 in
order to consider only the concentration of cis-flupentixol,
with the assumption, that cis- and trans-flupentixol plasma
concentrations are equal in flupentixol treated patients. As a
result, patients treated orally with 6–12 mg/day flupentixol
achieved maximally 10 ng/ml cis- + trans-flupentixol concen-
trations. However, in 1987, the same group (Balant-Gorgia
et al. 1987) developed a stereospecific assay which revealed
that in a group of patients treated orally with flupentixol, 59 %
of the patients had a trans-/cis-flupentixol ratio in plasma
between 1.5 and 2.5 (range 0.77–6.0). In 93 % of the cases,
the inactive trans-isomer concentration exceeded that of the
active cis-isomer. A graphic presentation suggests that in
patients treated orally with 4–15 mg/day flupentixol, cis-
flupentixol concentrations vary between 0.5 and 5 ng/ml.
This suggests that in the PET study (Reimold et al. 2007),
significantly lower concentrations than 0.5–2 ng/ml cis-
flupentixol lead to 50–70 % D2-receptor occupancy.
Other authors developed stereoeselective methods of flu-
pentixol in the blood of patients treated with flupentixol.
Ulrich (1995) described disappearance of cis-flupentixol
exposed to daylight and its trans-isomerization to trans-
flupentixol until a 1:1 mixture of both isomers is reached.
In the clinical part of his study, none of the few patients
treated with 20 mg/day flupentixol p.os had cis-flupixol
levels >10 ng/ml. After a treatment of dozens of patients
with 2.5–40 mg/day oral flupentixol, cis-flupentixol levels
were found to be <10 ng/ml in all but one patient. These
authors carefully avoided exposition of the probes to day-
light during drug analysis (Walter et al. 1998). In cocaine
dependent patients treated with low doses (2.5 or 5 mg/day)
of oral flupentixol, cis-flupentixol plasma trough levels as
measured with a stereoselective method only reached 0.53±
0.2 ng/ml (means ± SEM) (Evans et al. 2001).
Several authors did not mention the existence of cis–
trans isomerism of flupentixol in their publications, where
they proposed non-stereoselective assays for therapeutic
drug monitoring (Gutteck and Rentsch 2003; Kumazawa
et al. 2000).
In conclusion, considering the pharmacological and phar-
macokinetic differences between cis- and trans-flupentixol,
therapeutic monitoring studies with oral flupentixol in psy-
chiatric patients should include stereoselective assays in
conditions protected from daylight. Moreover, more data
are needed to clearly define an optimal therapeutic range
for cis-flupentixol plasma levels, as almost all studies were
performed in a limited number of patients treated with
relatively low doses (2.5–20 mg/day) of flupentixol.
Tentatively, a therapeutic reference range/recommended
cis-flupentixol concentration range of 0.5–5 ng/ml is
proposed.
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